A peptide program is a portfolio, not a SKU
If you are thinking about peptides as a single bucket called "regenerative peptides," that is the first thing to fix.
The substances that are currently moving through the FDA review process are clinically very different. They are intended for very different patient profiles. They have very different evidence bases, dosing patterns, and operational footprints.
For a telehealth team, that means peptides should be planned the same way GLP-1s are now planned in 2026, as a portfolio of products mapped to specific patient journeys, not as a generic catalog.
This post is a practical map. It groups the most discussed peptides by what they are actually used for, what kind of patient they fit, and what each one implies for program design. It is not a clinical efficacy review. It is meant to help operators decide which peptides belong in their first launch wave and which ones do not.
For the regulatory backdrop, see the companion piece, Regenerative Peptides in 2026: What Telehealth Teams Should Watch Before the July FDA Committee.
Group 1: Tissue and gut recovery peptides
This is the group that most clinicians refer to when they say "regenerative peptides." It is the most likely anchor for a telehealth recovery program if it lands cleanly on the 503A Bulks List.
Tissue and Gut Recovery
The anchor group of a recovery-focused telehealth program. Most often paired together in clinical protocols.
Most discussed peptide in the recovery category. Studied for soft tissue, joint, ligament, and GI mucosa support.
Most often paired with BPC-157. Positioned around wound healing, soft tissue flexibility, and post-injury recovery.
Anti-inflammatory peptide, with patient interest concentrated around gut health and certain skin conditions.
For a telehealth program, the natural patient profile is recovery-focused men's and women's health, joint and tendon support after injury or surgery, functional medicine and longevity programs, and certain gut health offerings.
Operationally, BPC-157 and TB-500 tend to be marketed and prescribed together. Programs that offer one and not the other usually create more confusion than they solve. KPV is usually a smaller line item, a good candidate for a follow-up wave once the core recovery offering is operating cleanly.
Group 2: Metabolic and longevity peptides
This is the group most adjacent to existing GLP-1 programs.
Metabolic and Longevity
The group most adjacent to existing GLP-1 programs. Natural cross-sell candidates for an established metabolic patient base.
Often called 'exercise in a vial.' Research interest around metabolism, insulin sensitivity, and obesity-adjacent indications.
Most discussed in the longevity context, including telomere-related research and sleep regulation.
For telehealth operators, MOTs-c is the most natural cross-sell candidate for an existing GLP-1 patient base. The patient profile, intake, and follow-up cadence overlap meaningfully with metabolic care that is already in production.
Epitalon belongs in a longevity-positioned program, not a generic recovery program. If you do not already have a longevity-shaped patient base, this is an awkward first peptide to launch with, even if the regulatory status improves.
Group 3: Neurocognitive peptides
This group is most often associated with focus, anxiety, and recovery from neurological events.
Neurocognitive
Most often associated with focus, anxiety, and recovery from neurological events. Best fit for a 'focus and brain fog' line.
Studied for cognitive enhancement, attention, neuroprotection, and certain stroke recovery contexts.
Studied in anxiety and cognitive contexts. On a separate FDA review track from the July 2026 PCAC agenda.
Niche addition for sleep-focused programs or longevity offerings with a clear sleep pillar.
For a telehealth program, the natural framing for Semax is a "focus and brain fog" or cognitive support line. The patient profile typically overlaps with sleep, stress, and high-performance professional segments.
Selank works alongside Semax in many operating models, but the two should not be marketed as a single product. They have different mechanisms and different evidence bases. DSIP is a niche addition that only makes sense in a program with a real sleep-medicine or longevity pillar.
Group 4: Growth hormone secretagogues
This is the most clinically established group on the list, even though it is on a different regulatory track from the July 2026 agenda.
Growth Hormone Secretagogues
The most clinically established group. Highest clinician familiarity, on a separate regulatory track from the July agenda.
Almost always prescribed with Ipamorelin. Used for sleep quality, lean body composition, recovery, and metabolic support.
Paired with CJC-1295 in standard protocols. Highest clinician comfort level of any peptide on the broader list.
For a telehealth team, this group is the easiest to operationalize from a clinical perspective. The clinician comfort level is higher, the dosing protocols are more standardized, and the patient education materials are more mature.
The trade-off is that this group sits in a more crowded competitive landscape. Many existing men's health and longevity programs already offer CJC-1295 and Ipamorelin combinations. A telehealth platform entering this space needs a clear reason for patients to choose it over an established program.
How to choose a launch wave
Most telehealth platforms cannot launch all of these at once and do it well. The right model is to pick a launch wave that fits the existing program and patient base.
A useful first cut:
- If your core program is GLP-1 weight management, the natural wave is MOTs-c first, then CJC-1295 and Ipamorelin if you have the clinical depth.
- If your core program is men's health or recovery, the natural wave is BPC-157 and TB-500 together, with KPV as a follow-up.
- If your core program is longevity, the natural wave is Epitalon and DSIP, ideally paired with a real sleep and recovery offering.
- If your core program is cognitive or executive performance, the natural wave is Semax and Selank, which need a different intake than a recovery program.
Trying to do all four groups at the same time is the easiest way to dilute clinical credibility and confuse the patient.
What this means for the operating layer
Whatever subset you choose, the underlying operating model has to be tighter than a typical supplement or wellness offering.
Intake
Peptide intake should look more like a real medical intake than a quiz. It needs medication history, allergy screening, contraindication checks, and the patient's actual goals captured in clinician-readable form. For the underlying mechanics, see Design Research for Intake Forms in GLP-1 Telehealth.
Clinical review
503A compounding requires an individualized prescription. That means a real clinician decision per patient, not an automated approval. Programs that try to template peptides into a one-click checkout will run straight into compliance and quality problems.
Pharmacy
Compounding pharmacy quality is the largest operational risk in this category. Sourcing, sterility, stability, and labeling all matter more than they do for higher-volume substances. The right pharmacy partner is one that can document its peptide workflow, not just one that can ship boxes. Pair this with How to Choose a Compounding Pharmacy for Your Telehealth Program.
Billing and refills
Peptide therapy is mostly self-pay. Cycle length, pricing, and refill timing have to be clear before the first charge. For the patterns that work in adjacent categories, see Billing UX for Telehealth and GLP-1 Refill Operations Workflow.
Marketing claims
Until the FDA finalizes 503A inclusion for any of these peptides, marketing should stay grounded in patient education, not therapeutic promises. That posture should hold even after inclusion, because compounded peptides are not FDA-approved drugs and should not be marketed as if they are.
Final takeaway
Regenerative peptides are likely to become a real telehealth category over the next twelve to twenty-four months. They will not become a single product. They will become a portfolio that telehealth platforms have to plan as deliberately as they plan their GLP-1 lineup today.
The teams that win in this category will be the ones that pick a tight launch wave, partner with the right compounding pharmacy, build a real clinical workflow, and treat marketing claims with discipline.
For the regulatory side of the picture, continue with Regenerative Peptides in 2026: What Telehealth Teams Should Watch Before the July FDA Committee. For the operating layer, continue with How to Launch a GLP-1 Telehealth Program.